Edition:
United States

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

5.71USD
20 Apr 2018
Change (% chg)

$-0.14 (-2.39%)
Prev Close
$5.85
Open
$5.81
Day's High
$5.85
Day's Low
$5.68
Volume
352,407
Avg. Vol
529,811
52-wk High
$7.00
52-wk Low
$3.50

Chart for

About

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $1,235.87
Shares Outstanding(Mil.): 216.44
Dividend: --
Yield (%): --

Financials

  TXMD.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -0.38 -- --
ROI: -59.77 13.60 13.19
ROE: -59.77 15.26 15.00

BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR

* ENTERED INTO NEGOTIATIONS WITH U.S. FOOD AND DRUG ADMINISTRATION REGARDING PROPOSED LABEL FOR TX-004HR

Apr 11 2018

BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr

* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR

Mar 08 2018

BRIEF-TherapeuticsMD Q4 Loss Per Share $0.10

* THERAPEUTICSMD ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 20 2018

BRIEF-TherapeuticsMD Submits New Drug Application For TX-001HR

* THERAPEUTICSMD ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TX-001HR

Dec 28 2017

BRIEF-Therapeuticsmd Announces FDA Acceptance Of New Drug Application And PDUFA Date For TX-004HR

* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-004HR

Dec 19 2017

BRIEF-TherapeuticsMD reports Q3 loss per share of $0.07

* TherapeuticsMD announces third quarter 2017 financial results

Nov 06 2017

BRIEF-TherapeuticsMD announces plan to resubmit the new drug application for TX-004HR

* TherapeuticsMD Inc announces plan to resubmit the new drug application for TX-004HR

Nov 06 2017

Earnings vs. Estimates